Lisata Therapeutics Inc. (NASDAQ: LSTA) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT LISATA THERAPEUTICS INC.

Lisata Therapeutics Inc. (NASDAQ: LSTA)
Listen to this Section


$2.63
-0.0840 ( -2.95% ) 5.4K

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Market Data


Open $2.63
Previous Close $2.71
Volume 5.4K
Market Cap $23.00M
Day Range $2.60 - $2.75
52 Week Range $2.19 - $4.20
Shares Outstanding 8.39M
Change % -2.95%
Net Change ▼ -0.0840
Insider Ownership -0.01%
Exchange NASDAQ
Sector Healthcare
Industry Misc Health and Biotechnology Services
IPO Year 1999
Country United States

Insider Ownership Transactions

Total Amount Purchased: -222,334.00

Date Type Amount Purchased Purchaser
2024-01-12 Sale -1026.00 Mazzo David J
2024-01-11 Sale -19480.00 KLOSK STEVEN M
2024-01-11 Sale -19480.00 HENSON HEIDI
2024-01-11 Sale -19480.00 AZAB MOHAMMAD
2024-01-11 Sale -94000.00 Mazzo David J
2024-01-11 Sale -19480.00 BROWN GREGORY B
2024-01-11 Sale -19480.00 Flowers Cynthia Louise
2024-01-11 Sale -27000.00 Buck Kristen K
2023-09-05 Sale -2908.00 Buck Kristen K

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
effect Other 1 May 09, 2024
10-q Quarterly Reports 82 May 09, 2024
8-k 8K-related 68 May 09, 2024
corresp Comment letters 2 May 07, 2024
upload Comment letters 2 May 06, 2024
s-3 Registration statements 5 May 01, 2024
defa14a Other 3 Apr 29, 2024
def Proxies and info statements 7 Apr 29, 2024
3 Insider transactions 2 Apr 24, 2024
8-k 8K-related 13 Apr 17, 2024

Latest News


× Before browsing our site, please accept our cookies policy